Trade

with

Emergent BioSolutions Inc
(NYSE: EBS)
AdChoices
21.45
-0.15
-0.69%
After Hours :
21.45
0.00
0.00%

Open

21.66

Previous Close

21.60

Volume (Avg)

166.49k (206.00k)

Day's Range

21.00-22.28

52Wk Range

18.28-28.48

Market Cap.

809.51M

Dividend Rate ( Yield )

-

Beta

1.08

Shares Outstanding

37.48M

P/E Ratio (EPS)

59.52 (0.36)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 312.74M

    • Net Income

    • 31.14M

    • Market Cap.

    • 809.51M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 3.84

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.08

    • Forward P/E

    • -

    • Price/Sales

    • 2.27

    • Price/Book Value

    • 1.65

    • Price/Cash flow

    • 15.75

      • EBITDA

      • 62.32M

      • Return on Capital %

      • 1.94

      • Return on Equity %

      • 2.88

      • Return on Assets %

      • 1.94

      • Book Value/Share

      • 13.02

      • Shares Outstanding

      • 37.48M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 20.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • 1.24

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 33.80

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • 32.40

          • 17.04

          • Net Income

            Q/Q (last year)

          • -52.00

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 11.86

          • 63.43

          • Net Income

            5-Year Annual Average

          • 8.50

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 73.54

            • 82.75

            • Pre-Tax Margin

            • 5.98

            • 39.38

            • Net Profit Margin

            • 3.84

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 82.40

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 16.00

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 11.60

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.51

              • 0.76

              • Current Ratio

              • 4.52

              • 2.92

              • Quick Ratio

              • 3.44

              • 2.35

              • Interest Coverage

              • 5.01

              • 38.02

              • Leverage Ratio

              • 1.72

              • 2.21

              • Book Value/Share

              • 13.02

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 58.82

                • 217.39

                • P/E Ratio 5-Year High

                • 78.43

                • 634.30

                • P/E Ratio 5-Year Low

                • 34.04

                • 124.82

                • Price/Sales Ratio

                • 2.26

                • 9.52

                • Price/Book Value

                • 1.64

                • 8.61

                • Price/Cash Flow Ratio

                • 15.75

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • 2.88

                        (9.80)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • 1.94

                        (7.20)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • 2.71

                        (8.20)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • 9.98k

                      • 117.08k

                      • Inventory Turnover

                      • 2.20

                      • 1.48

                      • Asset Turnover

                      • 0.50

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      42.80M
                      Operating Margin
                      13.69
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      15.75
                      Ownership

                      Institutional Ownership

                      83.70%

                      Top 10 Institutions

                      39.79%

                      Mutual Fund Ownership

                      40.82%

                      Float

                      78.10%

                      5% / Insider Ownership

                      7.06%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Dreyfus Opportunistic Small Cap Fund

                      •  

                        1,475,416

                      • 0.00

                      • 3.94

                      • iShares Core S&P Small-Cap (AU)

                      •  

                        593,182

                      • 0.20

                      • 1.60

                      • SPDR® S&P Biotech ETF

                      •  

                        565,504

                      • -1.93

                      • 1.53

                      • Vanguard Small Cap Index

                      •  

                        521,566

                      • -0.03

                      • 1.39

                      • Vanguard Total Stock Mkt Idx

                      •  

                        500,390

                      • 0.00

                      • 1.34

                      • Glenmede Small Cap Equity Portfolio

                      •  

                        487,547

                      • 34.86

                      • 1.30

                      • Loomis Sayles Small Cap Growth Fund

                      •  

                        448,541

                      • -3.58

                      • 1.20

                      • PowerShares Dynamic Biotech&Genome Port

                      •  

                        441,771

                      • 0.00

                      • 1.19

                      • iShares Russell 2000 (AU)

                      •  

                        435,885

                      • -1.45

                      • 1.18

                      • Vanguard Small Cap Growth Index Fund

                      •  

                        352,922

                      • -1.68

                      • 0.94

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Boston Co Asset Management LLC

                      •  

                        2,891,944

                      • +0.35%

                      • 7.72

                      • Broadfin Capital, LLC

                      •  

                        2,080,519

                      • +15.24%

                      • 5.55

                      • Vanguard Group, Inc.

                      •  

                        2,016,586

                      • +1.92%

                      • 5.38

                      • Dreyfus Corporation

                      •  

                        1,572,959

                      • 0.00%

                      • 4.20

                      • BlackRock Fund Advisors

                      •  

                        1,499,600

                      • -2.35%

                      • 4.00

                      • Dimensional Fund Advisors, Inc.

                      •  

                        1,476,073

                      • +15.46%

                      • 3.94

                      • State Street Corp

                      •  

                        1,219,071

                      • -2.91%

                      • 3.25

                      • Loomis Sayles & Company L.P.

                      •  

                        910,115

                      • +6.26%

                      • 2.43

                      • Numeric Investors LLC

                      •  

                        636,759

                      • +2.89%

                      • 1.70

                      • Renaissance Technologies Corp

                      •  

                        607,511

                      • -20.37%

                      • 1.62

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Slow Growth

                      Style

                      Small Growth

                      Emergent BioSolutions Inc., was incorporated as BioPort Corporation under the laws of Michigan in May 1998 and subsequently reorganized as a Delaware corporation in June 2004. The Company is a biopharmaceutical company, which is focu...moresed on the development, manufacture and commercialization of vaccine and immune-related therapeutic that assist the body’s immune system to prevent or treat disease. It develops vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism and biowarfare and infectious diseases that have resulted in significant unmet or underserved public health needs. The Company manufactures and markets BioThrax(r), also referred to as anthrax vaccine adsorbed, the only vaccine approved by the U.S. Food and Drug Administration, or FDA, for the p...morerevention of anthrax infection. BioThrax is approved for pre-exposure prevention of anthrax infection by all routes of exposure, including inhalation. The Company operates in two business segments, biodefense and biosciences. Its biodefense segment focuses on vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism or biowarfare. Its product candidates in this segment are focused on two specific biological agents: anthrax and botulinum. Within its anthrax product portfolio, the Company manufactures and markets BioThrax(r) (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. In addition to BioThrax, the Company is developing a recombinant protective antigen anthrax, or rPA, vaccine an advanced BioThrax vaccine, an anthrax immune globulin therapeutic and a recombinant anthrax monoclonal antibody therapeutic. Within its botulinum product portfolio, it is developing a recombinant botulinum vaccine. The Company’s Biosciences division is a specialty pharmaceutical business focused on therapeutics and vaccines in hematology/oncology, transplantation and infectious disease. The Company’s products and any product or product candidate that it acquires or successfully develop and commercialize is likely to compete with currently marketed products, such as vaccines, antibody therapies, antibiotics and other product candidates that are in development for the same indications. Specifically, the competition for its products and product candidates includes BioThrax, RSDL, BAT, AIGIV, VIGIV and PreviThrax and NuThrax. Accordingly, it is subject to federal, state, local and foreign laws and regulations governing the use, manufacture, distribution, storage, handling, disposal and recordkeeping of these materials.lessless

                      Key People

                      Daniel J. Abdun-Nabi

                      CEO/Director/President

                      Fuad El-Hibri

                      Chairman of the Board/Director

                      Mr. Robert G. Kramer,Sr

                      CFO/Chief Accounting Officer/Executive VP, Divisional/Treasurer

                      Anatolio B. Cruz,III

                      Executive VP/General Counsel/Secretary

                      Barry A. Labinger

                      Executive VP/President, Divisional

                      • Emergent BioSolutions Inc

                      • 2273 Research Boulevard

                      • Rockville, MD 20850

                      • USA.Map

                      • Phone: +1 301 795-1800

                      • Fax: +1 301 795-1899

                      • emergentbiosolutions.com

                      Incorporated

                      1998

                      Employees

                      1,353

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: